Partial Thromboplastin Time

Methodology: 
Electromagnetic endpoint detection
Performed: 
Monday - Friday
Reported: 
Within 24 hours
Use: 
Monitoring heparin therapy (unfractionated heparin); Screening for certain coagulation factor deficiencies; Detection of coagulation inhibitors such as lupus anticoagulant, specific factor inhibitors, and nonspecific inhibitors.
Specimen Requirements: 
Type: Plasma (sodium citrate, platelet-poor)
 

Container/Tube: Light blue (3.2 percent sodium citrate)

Sample Volume: 2 mL of platelet-poor plasma; 0.5 mL minimum

Storage:
  • Ambient: 4 hours
  • Frozen: 1 month

Unacceptable Conditions:

  • Clotted or hemolyzed samples
  • EDTA plasma
  • Serum
Specimen Retention Time: 5 days
Reference Values: 
25.2 – 34.9 seconds
CPT Code (s): 
85730
Notes: 

Aliases

  • PTT activated partial thromboplastin time
  • aPTT
  • Partial thromboplastin time
  • Partial thromboplastin time, activated

UFHPL Test #: 50005

UFHPL Epic order code: LAB325

UFHPL - Core Laboratory Recommendations for Anticoagulant Therapy

Although the prothrombin time (PT) and activated thromboplastin time (aPTT) are both affected by vitamin K antagonists (Coumadin) and by heparin, the PT/INR is the recommended first-line assessment of Coumadin therapy.

As an alternative to aPTT measurements for unfractionated heparin, a direct heparin assay can be performed. Heparin is measured as anti-Xa units. Indeed, this is the recommended modality of assessing low molecular weight heparin therapy, since the aPTT is a poor indicator of the response to LMW heparin.

There is increasing use of direct thrombin inhibitors, such as Argatroban. We recommend monitoring the latter with the aPTT using a prolongation of approximately 1.5 to 2.5 times the baseline.

Anticoagulation therapy monitoring should be done in careful consultation with the UF Health Pharmacy and the UF Department of Medicine, Division of Hematology.
Test Directory